-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Edit | Wang Duoyu Typesetting | A new wave of new crown epidemics caused by the Delta variant with more waterborne spread and higher viral load is exacerbating the global public health crisis, and many studies have shown that the existing vaccine is against the Delta variant The preventive ability of COVID-19 has declined.
Therefore, re-inoculation of booster shots for people who have been vaccinated with the new crown vaccine has become a potential demand for responding to the current new crown pandemic
.
On September 15, 2021, Moderna researchers published a paper titled: Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis in Nature Medicine, a sub-Journal of Nature
.
This vaccination study carried out on 80 people showed that Moderna's mRNA-1273 vaccine and the improved vaccine against variant strains are safe and well tolerated as booster injections, and can improve the key to focus on the new coronavirus variant strains (including Beta, Gamma, Delta variants) neutralizing antibody levels
.
In order to evaluate the safety and efficacy of the booster shot of the new crown vaccine, the researchers asked subjects who had received two shots of the Moderna vaccine (mRNA-1273) to receive a booster shot 6 months later
.
Their booster shots are either the original vaccine or an improved vaccine against variant strains, such as the mRNA-1273.
211 vaccine against multiple variant strains
.
Darin Edwards and colleagues observed four booster injection groups (20 subjects in each group, and the injected vaccine was a different combination of original and modified vaccines)
.
Immediately before the booster shot, the level of SARS-CoV-2 neutralizing antibody in the blood of the subjects was lower than their level one month after the second shot, and for those who need to pay attention to the mutant strains Beta, Gamma, and Delta Neutralizing antibody levels are either very low or undetectable
.
The authors found that the three booster injections they tested can make the subjects' SARS-CoV-2 neutralizing antibody titers higher than the level one month after the first round of vaccines, caused by mRNA-1273 and mRNA-1273.
211 The increase is particularly significant
.
In addition, all three booster injections can increase the neutralizing antibody titers against Beta, Gamma, Delta variants and other variants that require attention
.
The authors of the paper stated that the preliminary analysis still has some limitations, including the small sample size and the fact that the treatment groups on which the results are based are not randomly assigned
.
However, they believe that the trial's mRNA technology platform for SARS-CoV-2 that needs to focus on the testing of variant strains seems to be effective in strengthening needle research and development
.
Link to the paper: https:// open for reprinting, welcome to forward to Moments and WeChat groups
Therefore, re-inoculation of booster shots for people who have been vaccinated with the new crown vaccine has become a potential demand for responding to the current new crown pandemic
.
On September 15, 2021, Moderna researchers published a paper titled: Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis in Nature Medicine, a sub-Journal of Nature
.
This vaccination study carried out on 80 people showed that Moderna's mRNA-1273 vaccine and the improved vaccine against variant strains are safe and well tolerated as booster injections, and can improve the key to focus on the new coronavirus variant strains (including Beta, Gamma, Delta variants) neutralizing antibody levels
.
In order to evaluate the safety and efficacy of the booster shot of the new crown vaccine, the researchers asked subjects who had received two shots of the Moderna vaccine (mRNA-1273) to receive a booster shot 6 months later
.
Their booster shots are either the original vaccine or an improved vaccine against variant strains, such as the mRNA-1273.
211 vaccine against multiple variant strains
.
Darin Edwards and colleagues observed four booster injection groups (20 subjects in each group, and the injected vaccine was a different combination of original and modified vaccines)
.
Immediately before the booster shot, the level of SARS-CoV-2 neutralizing antibody in the blood of the subjects was lower than their level one month after the second shot, and for those who need to pay attention to the mutant strains Beta, Gamma, and Delta Neutralizing antibody levels are either very low or undetectable
.
The authors found that the three booster injections they tested can make the subjects' SARS-CoV-2 neutralizing antibody titers higher than the level one month after the first round of vaccines, caused by mRNA-1273 and mRNA-1273.
211 The increase is particularly significant
.
In addition, all three booster injections can increase the neutralizing antibody titers against Beta, Gamma, Delta variants and other variants that require attention
.
The authors of the paper stated that the preliminary analysis still has some limitations, including the small sample size and the fact that the treatment groups on which the results are based are not randomly assigned
.
However, they believe that the trial's mRNA technology platform for SARS-CoV-2 that needs to focus on the testing of variant strains seems to be effective in strengthening needle research and development
.
Link to the paper: https:// open for reprinting, welcome to forward to Moments and WeChat groups
